Posts tagged as: Dana Farber back to homepage
 |
Cellceutix Clinical Trials at Dana Farber and Beth Israel Deaconess Now Active(0) The day of dosing cancer patients with Kevetrin is drawing near according to news this morning from Cellceutix Corporation (OTCBB: CTIX). The Beverly, Massachusetts-based company said today that clinical trials for their novel anti-cancer drug have gone active at Harvard’s Dana-Farber Cancer Center and partner Beth Israel Deaconess Medical Center. Dosing should begin within Read More |
 |
Cellceutix Cancer Drug Expanding to Three Different Clinical Trials(0) There is starting to be a steady buzz across the web about Cellceutix Corporation (OTCBB: CTIX) and its novel cancer drug, Kevetrin™. For starters, the p53-activating drug is on tap to begin dosing patients with solid tumors any day now in clinical trials at the vaunted Harvard University’s Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center. Second, Cellceutix has reported that Beth Israel Read More |
 |
Cellceutix Files Amended IND for Novel p53 Anti-Cancer Drug(0) The countdown has begun for Cellceutix to begin testing their lead compound, anti-cancer drug Kevetrin, at Dana-Farber and Beth Israel Deaconess. After a mild setback with Formatech going bankrupt, the company has completed the necessary changes to the Investigational New Drug application related to Quality Control testing and stability studies through a new supplier and added the data to the IND. This is great news for biotech traders and Cellceutix faithful as investors are eager to see the new drug in humans because Read More |
|
Cellceutix Secures $1 Million; Clinical Trials on Tap for Cancer Drug(0) Mass High Tech ran the story last Thursday after Cellceutix Corporation (OTCBB: CTIX) submitted a regulatory filing with the Security and Exchange Commission related to securing the funds, but this morning the company released press discussing their securing of $1 million in financing for their planned clinical trials on Kevetrin™, their flagship anti-cancer drug. The trials are slated to be held at Harvard’s Dana-Farber Cancer Institute. Read More |
 |
Jim Boeheim and Cellceutix Team to Fight Cancer(0) Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a biopharmaceutical company developing a novel drug to treat cancers and cancers which have proven resistant to today’s cancer therapies (drug-resistant cancers),is pleased to announce that Syracuse University’s legendary men’s basketball coach Jim Boeheim has joined Cellceutix as an advisor to the Company. Read More |
 |
Cellceutix Files IND; Cancer Trials to be Held at Dana-Farber(0) Cellceutix Corporation (OTCBB:CTIX) has filed its Investigational New Drug (IND) application for Kevetrin™, a novel anti-cancer drug, with the U.S. Food and Drug Administration (FDA). The Company must now wait 30 calendar days before initiating Read More |
|
Cellceutix Pens Agreement with Dana-Farber for Cancer Drug Research(0) Cellceutix Corporation (OTCQB:CTIX) announced this morning that they have signed a Laboratory Services Research Support Agreement with Dana Farber/Partners CancerCare, Inc. The agreement outlines the collaborative and laboratory support for the planned clinical trials for Kevetrin™, Cellceutix’s novel compound as an indication for cancer. Read More |
OTCBB News
read more
Stay Informed
Dana-Farber to Host Cellceutix Trials
Diabetes Rate Growing Exponentially
According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.
